FreeDM2: Real-time CGM for type 2 diabetes on basal insulin.
A UK randomised trial in the largest insulin-treated type 2 cohort that NICE guidelines NG28 doesn't currently fund.
23 minutes ago
Article Archive
Browse all clinical evidence, news, and expert commentary
GLP-1 & Obesity
NG28 NICE GUIDELINES: The Flozin-First Era, and 810,000 More GLP-1 Patients
The February 2026 update to NG28 ends that era. Most newly diagnosed patients will now be offered an SGLT-2 inhibitor alongside metformin from the outset.
about 1 hour ago
Prescribing Safety
SCOUT: what the UTI trial adds to UK primary care prescribing
The SCOUT trial is the first pragmatic head-to-head comparison of all four commonly used UTI regimens in a single trial. The results reinforce rather than redraw the UK prescribing picture — but they do sharpen one key question for primary care.
Medicine Centralabout 1 hour ago
Prescribing Safety
The safety circuit breaker: redefining the diagnostic journey (Jess's Rule)
The mandate is clear: if a diagnosis remains unsubstantiated or symptoms escalate after three appointments — Reflect, Review, and Rethink. Three strikes and we rethink.
7 days ago
Prescribing Safety
Why CRP testing didn't cut antibiotic prescribing
The PRUDENCE trial tested point-of-care diagnostics across 2,639 patients in 13 countries. It didn't reduce antibiotic prescribing. The reason why matters more than the result.
7 days ago
AI & Digital Health
AI scribes and the changing shape of clinical documentation
Dr Frederick Reynolds, a GP using ambient scribes day-to-day, has written the kind of thoughtful, first-hand review these tools deserve.
Dr Frederick Reynolds7 days ago
Women's Health
LDL Elevation in Menopause - Interpreting Lipids in Primary Care
From raised LDL to a new non-hormonal drug class and the largest HRT safety study to date, this week is all menopause in primary care.
7 days ago
Women's Health
A new non-hormonal choice for hot flushes: NICE approves NK3 RAs
NICE has now recommended the first drug in a genuinely new class — Fezolinetant in TA1143. It's an NK3 receptor antagonist for moderate to severe menopausal vasomotor symptoms when HRT isn't suitable.
7 days ago
Women's Health
The largest HRT mortality study and what it means for UK primary care
No excess mortality after 14 years. No signal for cardiovascular or cancer deaths; plus a survival benefit in women after bilateral oophorectomy.
21 days ago
GLP-1 & Obesity
GLP-1 for Alzheimer's? EVOKE trial says no
The EVOKE trials are in, and the answer is no. Novo Nordisk has terminated the programme and discontinued the planned one-year extension of both trials.
27 days ago
Cardio Renal Metabolic
SGLT2 trial watch
When a patient stops a medication, the assumption is usually that the benefits stop too. The EMPA-KIDNEY post-trial follow-up, published in NEJM, checked if this is true for SGLT2 inhibitors in CKD.
27 days ago
Cardio Renal Metabolic
The Kidney Failure Risk Equation: who should we refer?
The kidney failure risk equation is now in NICE guidance. A new BJGP study from Greater Manchester found that, for most patients, the risk of death is much higher than the risk of needing dialysis.
27 days ago
Page 1